Lancet Market to grow at a CAGR of 7.8% during 2026 to 2035; Driven by Rising Prevalence of Diabetes and Increasing Demand for Reliable Blood Sampling Devices

Market Highlights

The Lancet Market size was valued at USD 2.05 Billion in 2025, and the market is projected to grow from USD 2.21 Billion in 2026 to USD 4.34 Billion by 2035, registering a CAGR of 7.8% during the forecast period 2026–2035.

Lancets are being used for diabetes or glucose tests, tests in infants, heel-stick screening tests, as well as for scarred emergency patients or severely burned patients.

The factors driving the market growth include growing incidence rate of contagious and non-contagious diseases, increasing prevalence of diabetes, and rising inclination towards home care and home diagnostics. However, the risk associated with blood transfusion is expected to hinder the market growth during the forecast period.

Segment Analysis

The Global Lancet Market based on type has been segmented into safety lancet and personal lancet. Safety lancets can be further divided into push-button safety lancets; pressure activated safety lancets and side button safety lancets. Based on end user, the market is segmented into the hospitals & clinics, diagnostic centers & pathology laboratories, home diagnostics, research and academic laboratories, and others.

Market Players

Market Research Future (MRFR) recognizes following companies as key players in the global lancet market that include Terumo Corporation (Japan), Bayer AG (Germany), HTL-STREFA S.A. (Poland), Sarstedt AG & Co. (Germany), Becton, Dickinson and Company (US), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio-One International GmbH  (US), Improve Medical Instruments Co. Ltd (US)  and others.

Regional Analysis

The Global Lancet Market, based on region, is divided into Europe, the Americas, Asia-Pacific, and the Middle East and Africa.

Europe held the largest share of the global lancet market. The Europe market demonstrated substantial growth in the market due to the growing demand and need for safe blood glucose tests in hospitals, clinics, diagnostics centers, etc. and the growth in insulin users.

The Americas held a substantial share in the global lancet market owing to the rise in the prevalence of diabetes and the increasing need for a diabetes diagnosis. Asia-Pacific was the fastest growing region in the global market and accounted for 19.1% market share in the global market in 2025. 

The growth in this region is attributed to the low manufacturing cost and low labor cost in the region. Moreover, the Middle East and Africa showed the least growth owing to low per capita income and lack of adequate healthcare spending.

Key Findings of the Study

• Hospitals represented the largest end-user channel for the Lancet Market in 2025, contributing roughly USD 0.94 billion in revenue.


• Diagnostic Laboratories are forecast to register the fastest end-user CAGR at 8.8% over the study period, propelled by decentralised point-of-care testing networks.


• Glucose Testing dominated the Lancet Market with an estimated 86% share in 2025, underscoring diabetes management as the primary demand engine.


• Hemoglobin Testing is expanding at a CAGR of 7.6% through 2035, supported by anaemia screening programmes in Sub-Saharan Africa and South Asia.